Two drugs used for decades to treat inflammatory forms of arthritis may also benefit some people with hand osteoarthritis (OA). That’s according to two new studies presented at the 2019 American College of Rheumatology (ACR) annual meeting in early November in Atlanta.
All posts byArthritis Foundation
Our Global Message to Strengthen Patient Voices Is Heard at EULAR
Patient voices are critical to finding a cure for OA and other forms of arthritis. That’s the message Arthritis Foundation Osteoarthritis (OA) Programs Director Angie Botto-van Bemden, PhD, is sharing at the2019 annual European Congress of Rheumatology (EULAR)in Madrid, June 12-15.Continue readingOur Global Message to Strengthen Patient Voices Is Heard at EULAR
Providing a Consistent Message for OA Disease Management
The Arthritis Foundation is partnering globally with other osteoarthritis (OA)-related patient advocacy organizations to develop consistent treatment management messaging for all health care providers (HCPs) who interact with OA patients. Currently, an OA patient may see different types of HCPs, depending on the stage of their disease and their location. It’s important that primary care doctors become familiar with all OA treatment options so they can work with patients to develop the best care plans.Continue readingProviding a Consistent Message for OA Disease Management
High Uric Acid Impacts OA
Diagnosing osteoarthritis (OA) through a medical history, physical exam and x-ray is fairly straightforward, but predicting the progression – or how much osteoarthritis will worsen in any one person – is much harder.Continue readingHigh Uric Acid Impacts OA